PDCD1 and cancer: The PD-1/PD-L1 pathway in the TME (tumor microenvironment) can inhibit the activation of effector T cells and promote the generation of Treg cells; this shows that PD-1-induced immune suppression may cause cancer cells to escape immune surveillance [13].